14 Perspectives of Aptamers for Medical Applications
461
230. Liang ZM, Peng YH, Chen Y, Long LL, Luo HJ, Chen YJ, Liang YL, Tian YH, Li SJ, Shi YS,
Zhang XM (2019) The BACE1-Specific DNA aptamer a1 rescues amyloid-β pathology and
behavioral deficits in a mouse model of Alzheimer’s disease. Nucl Acid Ther 29(6):359–366.
https://doi.org/10.1089/nat.2019.0812
231. Mhyre TR, Boyd JT, Hamill RW, Maguire-Zeiss KA (2012) Parkinson’s disease. Subcell
Biochem 65:389–455. https://doi.org/10.1007/978-94-007-5416-4_16
232. Mannironi C, Di Nardo A, Fruscoloni P, Tocchini-Valentini GP (1997) In vitro selection of
dopamine RNA ligands. Biochemistry 36(32):9726–9734. https://doi.org/10.1021/bi9700633
233. Álvarez-Martos I, Møller A, Ferapontova EE (2019) Dopamine binding and analysis in
undiluted human serum and blood by the RNA-aptamer electrode. ACS Chem Neurosci
10(3):1706–1715. https://doi.org/10.1021/acschemneuro.8b00616
234. McConnell EM, Ventura K, Dwyer Z, Hunt V, Koudrina A, Holahan MR, DeRosa MC (2019)
In Vivo Use of a Multi-DNA aptamer-based payload/targeting system to study dopamine
dysregulation in the central nervous system. ACS Chem Neurosci 10(1):371–383. https://doi.
org/10.1021/acschemneuro.8b00292
235. Atik A, Stewart T, Zhang J (2016) Alpha-synuclein as a biomarker for Parkinson’s disease.
Brain Pathol 26(3):410–418. https://doi.org/10.1111/bpa.12370
236. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, Pike B, Root H, Rubenstein J, Boyer R, Stenroos ES, Chandrasekharappa S, Athanassiadou A, Papapetropoulos T,
Johnson WG, Lazzarini AM, Duvoisin RC, Di Iorio G, Golbe LI, Nussbaum RL (1997)
Mutation in the alpha-synuclein gene identified in families with Parkinson’s disease. Science
276(5321):2045–2047. https://doi.org/10.1126/science.276.5321.2045
237. Tsukakoshi K, Harada R, Sode K, Ikebukuro K (2010) Screening of DNA aptamer which
binds to alpha-synuclein. Biotechnol Lett 32(5):643–648. https://doi.org/10.1007/s10529010-0200-5
238. Sun K, Xia N, Zhao L, Liu K, Hou W, Liu L (2017) Aptasensors for the selective detection
of alpha-synuclein oligomer by colorimetry, surface plasmon resonance and electrochemical
impedance spectroscopy. Sens Actuat B Chem 245:87–94
239. Ren X, Zhao Y, Xue F, Zheng Y, Huang H, Wang W, Chang Y, Yang H, Zhang J (2019)
Exosomal DNA aptamer targeting α-Synuclein aggregates reduced neuropathological deficits
in a mouse Parkinson’s disease model. Mol Ther Nucl Acids 17:726–740. https://doi.org/10.
1016/j.omtn.2019.07.008
240. Ni S, Yao H, Wang L, Lu J, Jiang F, Lu A, Zhang G (2017) Chemical modifications of nucleic
acid aptamers for therapeutic purposes. Int J Mol Sci 18(8). https://doi.org/10.3390/ijms18
081683
241. Kuwahara M, Sugimoto N (2010) Molecular evolution of functional nucleic acids with
chemical modifications. Molecules 15(8):5423–5444. https://doi.org/10.3390/molecules150
85423
242. Eulberg D, Klussmann S (2003) Spiegelmers: biostable aptamers. ChemBioChem 4(10):979–
983. https://doi.org/10.1002/cbic.200300663
243. Yamazaki S, Tan L, Mayer G, Hartig JS, Song JN, Reuter S, Restle T, Laufer SD, Grohmann
D, Kräusslich HG, Bajorath J, Famulok M (2007) Aptamer displacement identifies alternative
small-molecule target sites that escape viral resistance. Chem Biol 14(7):804–812. https://doi.
org/10.1016/j.chembiol.2007.06.003
244. Hafner M, Vianini E, Albertoni B, Marchetti L, Grüne I, Gloeckner C, Famulok M (2008)
Displacement of protein-bound aptamers with small molecules screened by fluorescence
polarization. Nat Protoc 3(4):579–587. https://doi.org/10.1038/nprot.2008.15
245. Macugen (pegaptanib sodium) Pharmacology Review (2004) From Drugs@FDA website.
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-756_Macugen_pharmr.pdf.
Accessed 20 July 2015
246. Tucker CE, Chen LS, Judkins MB, Farmer JA, Gill SC, Drolet DW (1999) Detection
and plasma pharmacokinetics of an anti-vascular endothelial growth factor oligonucleotideaptamer (NX1838) in rhesus monkeys. J Chromatogr B Biomed Sci Appl 732(1):203–212.
https://doi.org/10.1016/s0378-4347(99)00285-6
461
230. Liang ZM, Peng YH, Chen Y, Long LL, Luo HJ, Chen YJ, Liang YL, Tian YH, Li SJ, Shi YS,
Zhang XM (2019) The BACE1-Specific DNA aptamer a1 rescues amyloid-β pathology and
behavioral deficits in a mouse model of Alzheimer’s disease. Nucl Acid Ther 29(6):359–366.
https://doi.org/10.1089/nat.2019.0812
231. Mhyre TR, Boyd JT, Hamill RW, Maguire-Zeiss KA (2012) Parkinson’s disease. Subcell
Biochem 65:389–455. https://doi.org/10.1007/978-94-007-5416-4_16
232. Mannironi C, Di Nardo A, Fruscoloni P, Tocchini-Valentini GP (1997) In vitro selection of
dopamine RNA ligands. Biochemistry 36(32):9726–9734. https://doi.org/10.1021/bi9700633
233. Álvarez-Martos I, Møller A, Ferapontova EE (2019) Dopamine binding and analysis in
undiluted human serum and blood by the RNA-aptamer electrode. ACS Chem Neurosci
10(3):1706–1715. https://doi.org/10.1021/acschemneuro.8b00616
234. McConnell EM, Ventura K, Dwyer Z, Hunt V, Koudrina A, Holahan MR, DeRosa MC (2019)
In Vivo Use of a Multi-DNA aptamer-based payload/targeting system to study dopamine
dysregulation in the central nervous system. ACS Chem Neurosci 10(1):371–383. https://doi.
org/10.1021/acschemneuro.8b00292
235. Atik A, Stewart T, Zhang J (2016) Alpha-synuclein as a biomarker for Parkinson’s disease.
Brain Pathol 26(3):410–418. https://doi.org/10.1111/bpa.12370
236. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, Pike B, Root H, Rubenstein J, Boyer R, Stenroos ES, Chandrasekharappa S, Athanassiadou A, Papapetropoulos T,
Johnson WG, Lazzarini AM, Duvoisin RC, Di Iorio G, Golbe LI, Nussbaum RL (1997)
Mutation in the alpha-synuclein gene identified in families with Parkinson’s disease. Science
276(5321):2045–2047. https://doi.org/10.1126/science.276.5321.2045
237. Tsukakoshi K, Harada R, Sode K, Ikebukuro K (2010) Screening of DNA aptamer which
binds to alpha-synuclein. Biotechnol Lett 32(5):643–648. https://doi.org/10.1007/s10529010-0200-5
238. Sun K, Xia N, Zhao L, Liu K, Hou W, Liu L (2017) Aptasensors for the selective detection
of alpha-synuclein oligomer by colorimetry, surface plasmon resonance and electrochemical
impedance spectroscopy. Sens Actuat B Chem 245:87–94
239. Ren X, Zhao Y, Xue F, Zheng Y, Huang H, Wang W, Chang Y, Yang H, Zhang J (2019)
Exosomal DNA aptamer targeting α-Synuclein aggregates reduced neuropathological deficits
in a mouse Parkinson’s disease model. Mol Ther Nucl Acids 17:726–740. https://doi.org/10.
1016/j.omtn.2019.07.008
240. Ni S, Yao H, Wang L, Lu J, Jiang F, Lu A, Zhang G (2017) Chemical modifications of nucleic
acid aptamers for therapeutic purposes. Int J Mol Sci 18(8). https://doi.org/10.3390/ijms18
081683
241. Kuwahara M, Sugimoto N (2010) Molecular evolution of functional nucleic acids with
chemical modifications. Molecules 15(8):5423–5444. https://doi.org/10.3390/molecules150
85423
242. Eulberg D, Klussmann S (2003) Spiegelmers: biostable aptamers. ChemBioChem 4(10):979–
983. https://doi.org/10.1002/cbic.200300663
243. Yamazaki S, Tan L, Mayer G, Hartig JS, Song JN, Reuter S, Restle T, Laufer SD, Grohmann
D, Kräusslich HG, Bajorath J, Famulok M (2007) Aptamer displacement identifies alternative
small-molecule target sites that escape viral resistance. Chem Biol 14(7):804–812. https://doi.
org/10.1016/j.chembiol.2007.06.003
244. Hafner M, Vianini E, Albertoni B, Marchetti L, Grüne I, Gloeckner C, Famulok M (2008)
Displacement of protein-bound aptamers with small molecules screened by fluorescence
polarization. Nat Protoc 3(4):579–587. https://doi.org/10.1038/nprot.2008.15
245. Macugen (pegaptanib sodium) Pharmacology Review (2004) From Drugs@FDA website.
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-756_Macugen_pharmr.pdf.
Accessed 20 July 2015
246. Tucker CE, Chen LS, Judkins MB, Farmer JA, Gill SC, Drolet DW (1999) Detection
and plasma pharmacokinetics of an anti-vascular endothelial growth factor oligonucleotideaptamer (NX1838) in rhesus monkeys. J Chromatogr B Biomed Sci Appl 732(1):203–212.
https://doi.org/10.1016/s0378-4347(99)00285-6